Germline Polymorphisms Associated With the PSA Response in Men With Metastatic Prostate Cancer Treated With Androgen Deprivation Therapy
18 Years
N/A
Male
Prostate Cancer
Trial Information
Germline Polymorphisms Associated With the PSA Response in Men With Metastatic Prostate Cancer Treated With Androgen Deprivation Therapy
OBJECTIVES:
- To test the association between serum PSA response (< 4 ng/mL) at 7 months with
inherited variability of germline single nucleotide polymorphisms, in a set of
candidate genes, in patients with metastatic prostate cancer treated with combination
induction androgen-deprivation therapy comprising bicalutamide and goserelin.
OUTLINE: DNA extracted from whole blood or serum samples is analyzed for inherited
variability of germline single nucleotide polymorphisms.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosed with metastatic prostate cancer
- Accrued to SWOG-9346 and received androgen-deprivation therapy (ADT)
- Must have serum PSA values from the beginning to the end of 8 courses of ADT
- Must have whole blood or serum samples available
PATIENT CHARACTERISTICS:
- Caucasian and African-American participants
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Serum PSA values at 7 months
Safety Issue:
No
Principal Investigator
Kathleen A. Cooney, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Michigan Cancer Center
Authority:
Unspecified
Study ID:
CDR0000669307
NCT ID:
NCT01120262
Start Date:
February 2010
Completion Date:
Related Keywords:
- Prostate Cancer
- recurrent prostate cancer
- stage IV prostate cancer
- Prostatic Neoplasms
Name | Location |
|---|
